Citations

Clear

3216 citation(s) found for "Zhang, Z L".

LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
Hou, Xiaonan , Evans, Bradley J., VanBlaricom, Jamison L., Weroha, Saravut J., Cliby, William A. , Zhang, Qing

Mayo Clinic

Cancers | August 7, 2018 | Volume: 10 | Issue: 8 | Pages: 260

10.3390/cancers10080260 | PMID 30087253 Get It

Transforming growth factor beta (TGF-β) signaling has pleiotropic functions regulating cancer initiation, development, and metastasis, and also plays important roles in the interaction between stromal and cancer cells, making the pathway a potential therapeutic target. LY2157299 monohydrate (LY), an inhibitor of TGF-β receptor I (TGFBRI), was examined for its ability to inhibit ovarian cancer (OC) growth both in high-grade serous ovarian cancer (HGSOC) cell lines and xenograft models. Immunohistochemistry, qRT-PCR, and Western blot were performed to study the effect of LY treatment on expression of cancer- and fibroblast-derived genes. Results showed that exposure to TGF-β1 induced phosphorylation of SMAD2 and SMAD3 in all tested OC cell lines, but this induction was suppressed by pretreatment with LY. LY alone inhibited the proliferation, migration, and invasion of HGSOC cells in vitro. TGF-β1-induced fibroblast activation was blocked by LY. LY also delayed tumor growth and suppressed ascites formation in vivo. In addition, independent of tumor inhibition, LY reduces ascites formation in vivo. Using OVCAR8 xenograft specimens we confirmed the inhibitory effect of LY on TGF-β signaling and tumor stromal expression of collagen type XI chain 1 (COL11A1) and versican (VCAN). These observations suggest a role for anti-TGF-β signaling-directed therapy in ovarian cancer.
Drosophila melanogaster as a function-based high-throughput screening model for antinephrolithiasis agents in kidney stone patients
Ali, Sohrab N. , Dayarathna, Thamara, Ali, Aymon N., Osumah, Tijani , Cooper, Tyler T. , Zhang, Dongxing , Kim, Dajung , Kim, Rachel , Amant, Andre St., Tailly, Thomas , Yang, Jun , Luyt, Len, Burton, Jeremy P. , Razvi, Hassan , Leong, Hon S. , Leong, Hon S , Ahmed, Mohamed E. , Power, Nicholas Edgar , Amant, André H. St. , Hou, Jinqiang , Yang, Jun, Spagnuolo, Paul A.

Mayo Clinic

Disease Models & Mechanisms | August 6, 2018 | Volume: 11 | Issue: 11 | Pages: No page available

10.1242/dmm.035873 | PMID 30082495 Get It

ABSTRACT Kidney stone disease involves the aggregation of stone-forming salts consequent to solute supersaturation in urine. The development of novel therapeutic agents for this predominantly metabolic and biochemical disorder have been hampered by the lack of a practical pre-clinical model amenable to drug screening. Here, Drosophila melanogaster, an emerging model for kidney stone disease research, was adapted as a high-throughput functional drug screening platform independent of the multifactorial nature of mammalian nephrolithiasis. Through functional screening, the therapeutic potential of a novel compound commonly known as arbutin that specifically binds to oxalate, a key component of kidney calculi, was identified. Through isothermal titration calorimetry, high-performance liquid chromatography and atomic force microscopy, arbutin was determined to interact with calcium and oxalate in both free and bound states, disrupting crystal lattice structure, growth and crystallization. When used to treat patient urine samples, arbutin significantly abrogated calculus formation in vivo and outperformed potassium citrate in low pH urine conditions, owing to its oxalate-centric mode of action. The discovery of this novel antilithogenic compound via D. melanogaster, independent of a mammalian model, brings greater recognition to this platform, for which metabolic features are primary outcomes, underscoring the power of D. melanogaster as a high-throughput drug screening platform in similar disorders. This is the first description of the use of D. melanogaster as the model system for a high-throughput chemical library screen. This article has an associated First Person interview with the first authors of the paper.
Uncoupled Endothelial Nitric Oxide Synthase Enhances p-Tau in Chronic Traumatic Encephalopathy Mouse Model
Shin, Nara , Kim, Hyeong-Geug , Kwon, Hyeok Hee , Yi, Min‐Hee , Zhang, Enji, Kim, Jwa-Jin, Hong, Jinpyo , Lee, Sun Yeul , Lee, Won Hyung , Triantafillu, Ursula L., Kim, Cuk‐Seong , Kim, Yonghyun , Kim, Dong Woon , Kim, Yonghyun , Kim, Dong Woon , Shin, Hyo Jung , Kim, Sena , Baek, Hyunjung

Mayo Clinic

Antioxidants & Redox Signaling | August 2, 2018 | Volume: 30 | Issue: 13 | Pages: 1601-1620

10.1089/ars.2017.7280 | PMID 30070145 Get It

Aims: Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disease thought to be caused by repetitive traumatic brain injury (TBI) and subconcussive injuries. While hyperphosphorylation of tau (p-Tau), which is attributed to astrocytic tangles (ATs) and neurofibrillary tangles, is known to be involved in CTE, there are limited neuropathological or molecular data. By utilizing repetitive mild TBI (rmTBI) mouse models, our aim was to examine the pathological changes of CTE-associated structures, specifically the ATs. Results: Our rmTBI mouse models showed symptoms of depressive behavior and memory deficit, alongside an increased p-Tau expression in their neurons and astrocytes in both the hippocampus and cortex. rmTBI induced oxidative stress in endothelial cells and nitric oxide (NO) generation in astrocytes, which were mediated by hypoxia and increased hypoxia-inducible factor 1-α (HIF1α). There was also correlated decreased regional cerebral tissue perfusion units, mild activation of astrocytes and NFκB phosphorylation, increased expression of inducible nitric oxide synthase (iNOS), increased endothelial nitric oxide synthase (eNOS) uncoupling with decreased tetrahydrobiopterin, and increased expression of nitrotyrosine, NADPH oxidase 2 (Nox2)/nuclear factor (erythroid-derived 2) factor 2 (Nrf2) signaling proteins. Combined, these effects induced peroxynitrite formation and hyperphosphorylation of tau in the hippocampus and cortex toward the formation of ATs. Innovation: Our model features molecular pathogenesis events of CTE with clinically relevant latency periods. In particular, this is the first demonstration of an increased astrocytic iNOS expression in an in vivo model. Conclusion: We propose a novel mechanism of uncoupled eNOS and NO contribution to Tau phosphorylation and AT formation in rmTBI brain, toward an increased molecular understanding of the pathophysiology of human CTE.
Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance)
Blarigan, Erin L. Van , Ou, Fang‐Shu , Niedzwiecki, Donna , Zhang, Sui , Fuchs, Charles S. , Ogino, Shuji , Benson, A.B., Hantel, Alexander, Atkins, James N., Giovannucci, Edward L. , Meyerhardt, Jeffrey A. , Saltz, Leonard , Ogino, Shuji , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Niedzwiecki, Donna , Saltz, Leonard B. , Mayer, Robert J. , Venook, Alan P. , Song, Mingyang

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 23, 2018 | Volume: 27 | Issue: 10 | Pages: 1227-1230

10.1158/1055-9965.epi-18-0487 | PMID 30038051 Get It

Abstract Background: Higher intake of long-chain ω-3 polyunsaturated fatty acids and nuts, rich plant sources of unsaturated fats, after colon cancer diagnosis are associated with improved survival. It is not known whether the amount or the distribution of other types of fat is associated with survival after colon cancer. Methods: We prospectively examined postdiagnostic total, animal, and vegetable fats, as well as the saturated, monounsaturated, polyunsaturated, and trans fat in relation to disease-free survival among 1,011 patients with stage III colon cancer. Patients were enrolled between 1999 and 2001 at the onset of adjuvant chemotherapy and followed for recurrence or death through 2009. Results: During median follow-up of 7 years, we observed 305 deaths and 81 recurrences (total events: 386). Neither total nor any specific type of dietary fat examined was statistically significantly associated with risk of cancer recurrence or death from any cause (disease-free survival) after stage III colon cancer. Conclusions: The amount and type (animal, vegetable, saturated, monounsaturated, polyunsaturated, and trans) of dietary fat consumed after colon cancer does not appear to be substantially associated with risk of recurrence or survival. Impact: Neither total nor major types (animal, vegetable, saturated, monounsaturated, polyunsaturated, and trans) of dietary fat consumed after colon cancer was associated with cancer recurrence or survival. Cancer Epidemiol Biomarkers Prev; 27(10); 1227–30. ©2018 AACR.
p53 upregulated by HIF-1α promotes hypoxia-induced G2/M arrest and renal fibrosis in vitro and in vivo
Liu, Limin , Zhang, Peng , Bai, Ming , He, Lijie , Zhang, Lei , Liu, Ting , Yang, Zhen , Duan, Menglu, Liu, Minna , Liu, Baojian , Du, Rui , Qian, Qi , Sun, Shiren , Liu, Ting

Mayo Clinic

Journal of Molecular Cell Biology | July 18, 2018 | Volume: 11 | Issue: 5 | Pages: 371-382

10.1093/jmcb/mjy042 | PMID 30032308 Get It

Abstract Hypoxia plays an important role in the genesis and progression of renal fibrosis. The underlying mechanisms, however, have not been sufficiently elucidated. We examined the role of p53 in hypoxia-induced renal fibrosis in cell culture (human and rat renal tubular epithelial cells) and a mouse unilateral ureteral obstruction (UUO) model. Cell cycle of tubular cells was determined by flow cytometry, and the expression of profibrogenic factors was determined by RT-PCR, immunohistochemistry, and western blotting. Chromatin immunoprecipitation and luciferase reporter experiments were performed to explore the effect of HIF-1α on p53 expression. We showed that, in hypoxic tubular cells, p53 upregulation suppressed the expression of CDK1 and cyclins B1 and D1, leading to cell cycle (G2/M) arrest (or delay) and higher expression of TGF-β, CTGF, collagens, and fibronectin. p53 suppression by siRNA or by a specific p53 inhibitor (PIF-α) triggered opposite effects preventing the G2/M arrest and profibrotic changes. In vivo experiments in the UUO model revealed similar antifibrotic results following intraperitoneal administration of PIF-α (2.2 mg/kg). Using gain-of-function, loss-of-function, and luciferase assays, we further identified an HRE3 region on the p53 promoter as the HIF-1α-binding site. The HIF-1α–HRE3 binding resulted in a sharp transcriptional activation of p53. Collectively, we show the presence of a hypoxia-activated, p53-responsive profibrogenic pathway in the kidney. During hypoxia, p53 upregulation induced by HIF-1α suppresses cell cycle progression, leading to the accumulation of G2/M cells, and activates profibrotic TGF-β and CTGF-mediated signaling pathways, causing extracellular matrix production and renal fibrosis.
A Langendorff-like system to quantify cardiac pump function in adult zebrafish
Dvornikov, Alexey V. , Huttner, Inken G., Ma, Xiao , Santiago, Celine , Xu, Xiaolei , Dvornikov, Alexey V , Lin, Xueying , Zhang, Hong , Fatkin, Diane

Mayo Clinic

Disease Models & Mechanisms | July 16, 2018 | Volume: 11 | Issue: 9 | Pages: No page available

10.1242/dmm.034819 | PMID 30012855 Get It

ABSTRACT Zebrafish are increasingly used as a vertebrate model to study human cardiovascular disorders. Although heart structure and function are readily visualized in zebrafish embryos because of their optical transparency, the lack of effective tools for evaluating the hearts of older, nontransparent fish has been a major limiting factor. The recent development of high-frequency echocardiography has been an important advance for in vivo cardiac assessment, but it necessitates anesthesia and has limited ability to study acute interventions. We report the development of an alternative experimental ex vivo technique for quantifying heart size and function that resembles the Langendorff heart preparations that have been widely used in mammalian models. Dissected adult zebrafish hearts were perfused with a calcium-containing buffer, and a beat frequency was maintained with electrical stimulation. The impact of pacing frequency, flow rate and perfusate calcium concentration on ventricular performance (including end-diastolic and end-systolic volumes, ejection fraction, radial strain, and maximal velocities of shortening and relaxation) were evaluated and optimal conditions defined. We determined the effects of age on heart function in wild-type male and female zebrafish, and successfully detected hypercontractile and hypocontractile responses after adrenergic stimulation or doxorubicin treatment, respectively. Good correlations were found between indices of cardiac contractility obtained with high-frequency echocardiography and with the ex vivo technique in a subset of fish studied with both methods. The ex vivo beating heart preparation is a valuable addition to the cardiac function tool kit that will expand the use of adult zebrafish for cardiovascular research.
Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice
Qin, Qing , Mehta, Hemal H. , Navarrete, Gerardo, Brandhorst, Sebastian , Wan, Junxiang , Delrio, Silvia , Zhang, Xin , Lerman, Lilach O. , Cohen, Pinchas , Yen, Kelvin , Lerman, Amir , Cohen, Pinchas

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | July 13, 2018 | Volume: 315 | Issue: 5 | Pages: H1127-H1136

10.1152/ajpheart.00685.2017 | PMID 30004252 Get It

Cardiac fibrosis is a biological process that increases with age and contributes to myocardial dysfunction. Humanin (HN) is an endogenous mitochondria-derived peptide that has cytoprotective effects and reduces oxidative stress. The present study aimed to test the hypothesis that chronic supplementation of exogenous HN in middle-aged mice could prevent and reverse cardiac fibrosis and apoptosis in the aging heart. Female C57BL/6N mice at 18 mo of age received 14-mo intraperitoneal injections of vehicle (old group; n = 6) or HN analog (HNG; 4 mg/kg 2 times/wk, old + HNG group, n = 8) and were euthanized at 32 mo of age. C57BL/6N female mice (young group, n = 5) at 5 mo of age were used as young controls. HNG treatment significantly increased the ratio of cardiomyocytes to fibroblasts in aging hearts, as shown by the percentage of each cell type in randomly chosen fields after immunofluorescence staining. Furthermore, the increased collagen deposition in aged hearts was significantly reduced after HNG treatment, as indicated by picrosirius red staining. HNG treatment also reduced in aging mice cardiac fibroblast proliferation (5′-bromo-2-deoxyuridine staining) and attenuated transforming growth factor-β1, fibroblast growth factor-2, and matrix metalloproteinase-2 expression (immunohistochemistry or real-time PCR). Myocardial apoptosis was inhibited in HNG-treated aged mice (TUNEL staining). To decipher the pathway involved in the attenuation of the myocardial fibrosis by HNG, Western blot analysis was done and showed that HNG upregulated the Akt/glycogen synthase kinase -3β pathway in aged mice. Exogenous HNG treatment attenuated myocardial fibrosis and apoptosis in aged mice. The results of the present study suggest a role for the mitochondria-derived peptide HN in the cardioprotection associated with aging. NEW & NOTEWORTHY Cardiac fibrosis is a biological process that increases with age and contributes to myocardial dysfunction. Humanin is an endogenous mitochondria-derived peptide that has cytoprotective effects and reduces oxidative stress. Here, we demonstrate, for the first time, that exogenous humanin treatment attenuated myocardial fibrosis and apoptosis in aging mice. We also detected upregulated Akt/glycogen synthase kinase-3β pathway in humanin analog-treated mice, which might be the mechanism involved in the cardioprotective effect of humanin analog in aging mice.
Objective but Not Subjective Short Sleep Duration Is Associated With Hypertension in Obstructive Sleep Apnea
Ren, Rong , Covassin, Naima , Yang, Linghui , Zhang, Ye , Zhou, Junying , Tan, Lu, Li, Taomei , Li, Xiao , Wang, Yanyan , Zhang, Jihui , Tang, Xiangdong , Tang, Xiangdong , Li, Yun , Tan, Lu, Wing, Yun Kwok , Li, Weimin , Somers, Virend K.

Mayo Clinic

Hypertension | July 9, 2018 | Volume: 72 | Issue: 3 | Pages: 610-617

10.1161/hypertensionaha.118.11027 | PMID 29987105 Get It

Extremes of sleep duration and obstructive sleep apnea (OSA) are both associated with hypertension. We aimed to explore whether sleep duration modifies the relationship between OSA and prevalent hypertension, using both objective and subjective measures of total sleep duration. A total of 7107 OSA patients and 1118 primary snorers were included in the study. Hypertension was defined based either on direct blood pressure measures or on diagnosis by a physician. Objective sleep duration was derived by polysomnography and subjective sleep duration was self-reported. Logistic regression models were used to estimate the associations between objective/subjective sleep duration and hypertension prevalence in OSA and primary snorers. Compared with primary snorers, OSA combined with objective sleep duration of 5 to 6 hours increased the odds of hypertension by 45% (odds ratio, 1.45; 95% confidence interval, 1.14–1.84), whereas OSA combined with objective sleep duration <5 hours further increased the odds of hypertension by 80% (odds ratio, 1.80; 95% confidence interval, 1.33–2.42). These results were independent of major confounding factors frequently associated with OSA or hypertension. In stratified analysis by sleep duration, risk of hypertension in those with extremely short sleep (<5 hours) was not significantly different between OSA and primary snorers, whereas odds were significant for OSA in the other 4 sleep duration strata (5–6, 6–7, 7–8, and >8 hours). No significance was evident using subjective sleep duration. We conclude that objective short sleep duration is associated with hypertension in OSA patients. Extremely short sleep duration in itself may actually be even more detrimental than OSA in terms of hypertension risk.
Author response: H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers
Dong, Fang , Gan, Haiyun , Cheng, Liang , Zhou, Hui , Lee, Jeong‐Heon , Sarkaria, Jann N. , Daniels, David J. , Zhang, Zhiguo

Mayo Clinic

No container title available | July 5, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.36696.031 Get It